This observational study, called PROSPECT, aims to understand why some cancers in the chest, like lung cancer, become resistant to treatment. Researchers will analyze tissue samples from up to 7200 patients with stage I-IIIA non-small cell lung cancer (NSCLC) who have had surgery, with or without chemotherapy before surgery. They will look at how different molecular factors in these samples relate to treatment resistance, how long patients live, and how cancer spreads. The goal is to find new ways to target these cancers and overcome resistance. This study is not testing a new treatment, but rather collecting information to help develop future treatments. The study will measure these factors over an average of one year.

Study design

This is an observational study planning to include up to 7200 participants. It is not testing a new treatment, but rather collecting information from existing tissue samples.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.